NHS Cost-Effectiveness Thresholds Boost Drug Ap...

By João L. Carapinha

January 12, 2026

Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals